Viking CEO on ‘shocking’ market reaction to oral obesity data, preparing for Phase 3news2024-11-05T11:30:59+00:00November 5th, 2024|Endpoints News|
FDA cites Mark Cuban’s drug compounding center in Dallas with sterility, quality concernsnews2024-11-04T21:14:27+00:00November 4th, 2024|Endpoints News|
The election is Tuesday. What’s at stake for the pharma industry?news2024-11-04T21:07:35+00:00November 4th, 2024|Endpoints News|
Rare disease biopharma companies weigh in on FDA’s new innovation hubnews2024-11-04T20:14:53+00:00November 4th, 2024|Endpoints News|
BioNTech eases 2024 revenue outlook despite hefty Covid vaccine third-quarter salesnews2024-11-04T18:46:43+00:00November 4th, 2024|Endpoints News|
FDA expands faster drug review pilot from supplemental to full applicationsnews2024-11-04T18:07:00+00:00November 4th, 2024|Endpoints News|
BioNTech says VEGF bispecific’s PD-L1 target, combo plans will be its edgenews2024-11-04T16:40:16+00:00November 4th, 2024|Endpoints News|
Novo, Ascendis to work on monthly GLP-1; KalVista makes a royalty dealnews2024-11-04T16:20:06+00:00November 4th, 2024|Endpoints News|
‘We play to win’: AstraZeneca details first results for oral GLP-1 and broader obesity ambitionsnews2024-11-04T15:55:13+00:00November 4th, 2024|Endpoints News|
MASH drug developers chart path forward as more patients use GLP-1snews2024-11-04T15:00:55+00:00November 4th, 2024|Endpoints News|
